Zepbound Resolution Dates: When Strengths Restock

Introduction

The FDA declared Zepbound® resolved on the shortage list on December 19, 2024, but pharmacy-level supply for higher strengths still varies in 2026. This piece walks through Eli Lilly’s manufacturing guidance for each strength and what to expect at the pharmacy level.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

What Does Eli Lilly’s Resolution Date Guidance Say?

Lilly’s Q4 2025 earnings call projected that tirzepatide manufacturing capacity would reach the level required to support consistent retail supply across all strengths by Q4 2026 to Q1 2027. CEO David Ricks stated publicly that the company is targeting 100 million U.S. patients on tirzepatide by 2030, which requires roughly tenfold capacity expansion from current levels.

Quick Answer: FDA removed Zepbound from the shortage list December 19, 2024

The Lebanon, Indiana site (announced 2020, first commercial production late 2025) added meaningful injectable peptide capacity. The Concord, North Carolina expansion came online in early 2025 for fill-finish. A new Mount Vernon, Indiana site is targeting 2027 for first commercial output.

Q1 2026 earnings reported total U.S. dispensing of approximately 4.2 million tirzepatide pen-equivalents per month, up from 1 million in mid-2023.

Zepbound 2.5 Mg Resolution Status

Resolved at all levels through 2025 and 2026. The 2.5 mg starter strength is consistently stocked at retail, mail-order, and direct channels. New patient starts have not faced systematic supply issues since early 2025.

If a specific pharmacy can’t fill 2.5 mg, the issue is local. The Zepbound Stock Locator at zepbound.lilly.com shows pharmacy-level inventory and is more accurate than the equivalent Wegovy® tool.

Zepbound 5 Mg Resolution Status

Resolved at all levels. The 5 mg titration dose has been consistently stocked since mid-2025. Patients moving from 2.5 mg during weeks 5-8 of therapy generally don’t experience supply gaps.

Zepbound 7.5 Mg Resolution Status

Largely resolved at the manufacturer level. Retail pharmacy supply normalized in Q4 2025 to Q1 2026. Occasional 3 to 7 day gaps occur regionally but are not systemic.

If your pharmacy can’t fill 7.5 mg, mail-order through your insurance plan or LillyDirect Self-Pay vials typically have it.

Zepbound 10 Mg Resolution Status

Manufacturer-level resolution achieved by Q4 2025 for vials, Q1 to Q2 2026 for KwikPens. Retail pharmacy normalization at the pen form expected Q2 to Q3 2026.

The 10 mg dose is where many patients land for maintenance after titration, especially patients who don’t tolerate or don’t need the higher 12.5 or 15 mg doses. Demand is steady and broad.

Specific 2026 status: vials at 10 mg are widely available through LillyDirect Self-Pay at $499 per month. KwikPen retail availability varies by region with occasional 5 to 10 day gaps in some markets.

Zepbound 12.5 Mg Resolution Status

Manufacturer-level resolution is targeted for Q3 to Q4 2026 per Lilly’s Q4 2025 guidance. Pharmacy-level normalization at KwikPen form is expected Q4 2026 to Q1 2027.

The 12.5 mg dose sits between titration steps that many patients pass through quickly (10 mg) and the maintenance dose that produces the largest SURMOUNT-1 trial outcomes (15 mg at 20.9% mean weight loss). Patients staying on 12.5 mg as long-term therapy add to demand.

12.5 mg vials are typically available through LillyDirect Self-Pay with 5 to 10 day shipping. 12.5 mg KwikPens at retail face the most consistent gaps in 2026 outside of 15 mg.

Zepbound 15 Mg Resolution Status

This is the slowest strength to fully normalize. Manufacturer-level resolution is targeted for Q4 2026 per Lilly’s most recent guidance. Pharmacy-level normalization at KwikPen form is expected Q1 to Q2 2027.

The 15 mg dose is the most-studied tirzepatide dose for weight loss. SURMOUNT-1 (Jastreboff et al. 2022 NEJM) reported 20.9% mean weight loss at 72 weeks at this dose. SURMOUNT-5 (Aronne et al. 2025 NEJM) head-to-head with semaglutide reported 20.2% versus 13.7%. Clinical preference drives sustained demand at 15 mg.

Specific 2026 channels: LillyDirect Self-Pay vials at 15 mg ship consistently with 5 to 10 day windows at $499 per month. Mail-order through insurance plans typically fills 15 mg vials within 5 to 10 business days. KwikPen retail availability is the tightest, with regional gaps of 7 to 28 days in some markets.

Key Takeaway: Single-dose vials normalized faster than KwikPens because vial filling has more capacity

Why Are Pens Slower Than Vials to Normalize?

Three reasons. Pen manufacturing requires multi-component assembly. The KwikPen has a body, a plunger, a needle assembly, a cartridge, and labeling that all need to come together on a sterile assembly line. Each component has its own supply chain.

Pen components come from specialty manufacturers. SHL Medical, Owen Mumford, and a few other firms supply the global pen device market. Lilly has been in-sourcing more of this supply chain in 2025 and 2026, but vertical integration takes years.

Vial filling is comparatively simple. Sterile drug substance is filled into glass vials, sealed, labeled, and packaged. Lilly’s vial fill-finish capacity grew faster than autoinjector capacity through 2025.

This is why LillyDirect Self-Pay ships only vials, not pens. The vial supply chain has slack that the pen supply chain doesn’t.

What About Mounjaro® Resolution Dates?

Mounjaro is the same molecule (tirzepatide) as Zepbound, made at the same factories. Resolution dates for Mounjaro strengths follow the same pattern: 2.5 mg and 5 mg fully resolved, 7.5 mg and 10 mg largely resolved, 12.5 mg and 15 mg slowest.

The two brands compete for the same fill-finish capacity at Lilly’s plants. Allocation between Mounjaro (diabetes) and Zepbound (obesity) can shift based on demand and contract considerations, but the underlying supply constraint is the same.

How Do Resolution Dates Affect My Refill Planning?

Three implications. If you’re on 2.5 mg or 5 mg, supply is not an issue. Plan normally.

If you’re on 7.5 mg or 10 mg, expect occasional regional gaps. Build a 10-day buffer into your refill cycle. Consider 90-day mail-order or LillyDirect Self-Pay vials.

If you’re on 12.5 mg or 15 mg, build a 21-day buffer. Use mail-order or LillyDirect Self-Pay as primary channels rather than retail. Have a contingency plan with your prescriber for a temporary dose drop if a longer gap hits.

By 2027, all Zepbound strengths should be at consistent retail availability absent new demand surges from indication approvals or pricing changes.

What About Future Indication Approvals?

SURMOUNT-OSA led to FDA approval for obstructive sleep apnea in December 2024, expanding the eligible patient population. SYNERGY-NASH (phase 2 for non-alcoholic steatohepatitis) is in phase 3 development. SURMOUNT-MMO (cardiovascular outcomes) is enrolling.

Each new indication approval expands demand. Lilly’s capacity guidance assumes specific growth rates that future approvals could exceed.

The most likely 2026 to 2027 demand drivers are pediatric obesity indication (in clinical trials), pediatric type 2 diabetes (separate trials), and chronic kidney disease in patients with obesity-related kidney pathology.

What Can Disrupt the Resolution Timeline?

Several things could push dates out. Indication approvals that expand demand faster than capacity (SURMOUNT-OSA was an example). Pricing changes that shift demand patterns (Medicare negotiation effects in 2027). Manufacturing setbacks at Lilly plants or supplier failures. Regulatory changes that affect supply chain.

Conversely, demand softening could accelerate normalization. New entrants in the GIP/GLP-1 class (Lilly’s retatrutide, Novo’s CagriSema) could divert some demand once approved. Generic semaglutide and tirzepatide are years away but eventually arrive.

Bottom line: LillyDirect Self-Pay and mail-order channels reach restock dates ahead of retail

FAQ

Will Lilly Meet Its 2026 to 2027 Resolution Targets?

Probably for most strengths, with some risk on 12.5 mg and 15 mg KwikPens. New indication approvals could push timing.

How Do I Track Current Zepbound Stock?

Use the Zepbound Stock Locator at zepbound.lilly.com. It refreshes several times per day and is more accurate than the Wegovy equivalent.

Why Doesn’t the FDA Relist Zepbound If 15 Mg Is Still Tight?

Same reason as with Wegovy 2.4 mg. The FDA shortage designation is a national binary based on aggregate supply and demand. Localized or strength-specific gaps don’t trigger relisting.

Is Compounded Tirzepatide Still Available?

Yes, through state-licensed 503A pharmacies on a patient-specific basis when there’s clinical justification. TrimRx works with licensed pharmacies that meet current FDA guidance.

Should I Switch to Wegovy While Waiting for Zepbound 15 Mg?

That depends on your clinical situation and your prescriber’s judgment. SURMOUNT-5 head-to-head data favors tirzepatide for weight loss, but switching requires new PA and re-titration.

When Will Pen Production Fully Catch Up?

Lilly’s guidance suggests Q1 2027 for the highest-volume pen strengths. Mount Vernon, Indiana site activation in 2027 will add meaningful capacity.

Does LillyDirect Self-Pay Show Resolution Dates?

LillyDirect’s specialty pharmacy publishes typical shipping windows of 5 to 10 business days for all vial strengths. Gaps in that channel have been rare in 2026.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.